N4 101
Alternative Names: N4-101Latest Information Update: 09 Jan 2026
At a glance
- Originator N4 Pharma
- Class Anti-inflammatories; RNA; Small interfering RNA
- Mechanism of Action RNA interference; Tumour necrosis factor alpha expression inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Inflammatory bowel diseases
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 04 Dec 2025 N4 101 is available for licensing as of 04 Dec 2025. https://n4pharma.com/partnership-opportunities (N4 Pharma pipeline, December 2025)
- 12 May 2025 Pharmacodynamics data from a preclinical trial in Inflammatory bowel disease released by N4 Pharma
- 12 Dec 2024 Preclinical trials in Inflammatory bowel diseases in United Kingdom (PO) (N4 Pharma pipeline, December 2025)